Company profile
Mitsubishi Tanabe Pharma
Diversified pharma (part of Mitsubishi Chemical Group)
Privately held: no public share price · Japan
Assets
(5 total)
5Total Assets
0Approved
4Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
AST-120(Kremezin) | Phase 3 | Oral spherical carbon adsorbentSmall molecule | Chronic Kidney Disease |
| Phase 3 | Phosphate binderSmall molecule | Chronic Kidney Disease | |
MP-513No recent activity | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
Teneligliptin(Tenelia) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
| Phase 2 | S1P receptorSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis, Crohn's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.